Literature DB >> 23812967

Understanding clinic options for overactive bladder.

Jamie M Bartley1, Emily S Blum, Larry T Sirls, Kenneth M Peters.   

Abstract

Overactive bladder (OAB) is a symptom complex of urinary frequency, nocturia and urgency with or without urgency incontinence that adversely impacts patient's quality of life. Conservative management begins in the outpatient clinic, often with significant improvement and patient satisfaction. In this review we will discuss the evaluation of OAB and review treatment options focusing on behavioral modification, medical therapy, and neuromodulation. These treatment options are offered in a stepwise fashion, remembering that more than one may be needed and can be used concomitantly.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23812967     DOI: 10.1007/s11934-013-0353-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  68 in total

Review 1.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

2.  A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.

Authors:  Ralph Peeker; Göran Samsioe; Jan Kowalski; Ann-Sofie Andersson; Agneta Bergqvist
Journal:  Scand J Urol Nephrol       Date:  2010-04

3.  Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.

Authors:  Debra E Irwin; Zoe S Kopp; Barnabie Agatep; Ian Milsom; Paul Abrams
Journal:  BJU Int       Date:  2011-01-13       Impact factor: 5.588

4.  Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).

Authors:  Amar Mohee; Ayisha Khan; Neil Harris; Ian Eardley
Journal:  BJU Int       Date:  2012-06-06       Impact factor: 5.588

5.  A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation.

Authors:  K Everaert; W Kerckhaert; H Caluwaerts; M Audenaert; H Vereecke; G De Cuypere; A Boelaert; U Van den Hombergh; W Oosterlinck
Journal:  Eur Urol       Date:  2004-05       Impact factor: 20.096

6.  The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.

Authors:  Karin S Coyne; Chris C Sexton; Debra E Irwin; Zoe S Kopp; Con J Kelleher; Ian Milsom
Journal:  BJU Int       Date:  2008-06       Impact factor: 5.588

7.  Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.

Authors:  Kathryn L Burgio; Stephen R Kraus; Shawn Menefee; Diane Borello-France; Marlene Corton; Harry W Johnson; Veronica Mallett; Peggy Norton; Mary P FitzGerald; Kimberly J Dandreo; Holly E Richter; Thomas Rozanski; Michael Albo; Halina M Zyczynski; Gary E Lemack; Toby C Chai; Salil Khandwala; Jan Baker; Linda Brubaker; Anne M Stoddard; Patricia S Goode; Betsy Nielsen-Omeis; Charles W Nager; Kimberly Kenton; Sharon L Tennstedt; John W Kusek; T Debuene Chang; Leroy M Nyberg; William Steers
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

8.  Impact of overactive bladder on work productivity in the United States: results from EpiLUTS.

Authors:  Chris C Sexton; Karin S Coyne; Vasudha Vats; Zoe S Kopp; Debra E Irwin; Todd H Wagner
Journal:  Am J Manag Care       Date:  2009-03       Impact factor: 2.229

9.  Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women.

Authors:  Philippe Zimmern; Heather J Litman; Elizabeth Mueller; Peggy Norton; Patricia Goode
Journal:  BJU Int       Date:  2009-11-13       Impact factor: 5.588

10.  Patient-reported reasons for discontinuing overactive bladder medication.

Authors:  Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker
Journal:  BJU Int       Date:  2009-11-12       Impact factor: 5.588

View more
  6 in total

1.  An overlooked effect of systemic anticholinergics: alteration on accommodation amplitude.

Authors:  Mehmet Ali Sekeroglu; Emre Hekimoglu; Mustafa Alpaslan Anayol; Yasemin Tasci; Ismail Dolen
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Effect of combined systematized behavioral modification education program with desmopressin in patients with nocturia: a prospective, multicenter, randomized, and parallel study.

Authors:  Sung Yong Cho; Kyu-Sung Lee; Jang Hwan Kim; Ju Tae Seo; Myung-Soo Choo; Joon Chul Kim; Jong Bo Choi; Miho Song; Ji-Youn Chun; Seung-June Oh
Journal:  Int Neurourol J       Date:  2014-12-29       Impact factor: 2.835

Review 3.  Evaluation and management of overactive bladder: strategies for optimizing care.

Authors:  Marcella G Willis-Gray; Alexis A Dieter; Elizabeth J Geller
Journal:  Res Rep Urol       Date:  2016-07-27

Review 4.  A comparison of sacral neuromodulation vs. transvaginal electrical stimulation for the treatment of refractory overactive bladder: the impact on quality of life, body image, sexual function, and emotional well-being.

Authors:  Valentina Lucia La Rosa; Alessio Platania; Michał Ciebiera; Simone Garzon; Robert Jędra; Marco Ponta; Salvatore Butticè
Journal:  Prz Menopauzalny       Date:  2019-06-28

5.  Variable- versus constant-frequency sacral neuromodulation in black-zone overactive bladder patients: a study protocol for a multicenter, prospective, randomized, blind, self-controlled trial.

Authors:  Lingfeng Meng; Zijian Tian; Tongxiang Diao; Miao Wang; Xiaodong Liu; Wei Zhang; Jianye Wang; Yaoguang Zhang
Journal:  Transl Androl Urol       Date:  2021-01

6.  Electroanatomical Mapping of the Urinary Bladder.

Authors:  Fawzy Farag; Martin Koens; Marij Tijssen; Sytse de Jong; Timon Fabius; Johnny Tromp; Hendrikje van Breda; Joep Smeets; Wout Feitz; John Heesakkers
Journal:  Int Neurourol J       Date:  2016-06-24       Impact factor: 2.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.